Brain cancer is a tumor that starts and stays in the brain, such as a glioma. It is further classified as benign brain cancer or malignant brain cancer. Benign brain cancer is a type of cancer that rarely spreads and invades surrounding tissue, has sharp borders, and has very slow cell growth. Examples of benign brain tumors include pituitary tumors, meningiomas, and astrocytomas; whereas malignant brain cancers are cancers that easily invade other parts of the brain and spinal cord, lack sharp borders, and have rapidly growing cells. Examples of malignant brain cancers include high-grade astrocytoma, oligodendroglioma, and others. Malignant brain cancer is the most aggressive of all cancers. It has had a huge impact on people's lives due to the failure of the therapeutic effects of currently employed strategies. Therefore, it is necessary to further explore the molecular mechanism of brain cancer in order to find effective drugs for the treatment of brain cancer as soon as possible. CD BioSciences provides precise In Vivo transfection services of brain cancer to assist in the study of the molecular functions of brain cancer-related genes.

Target Genes Delivered In Vivo in Brain Cancer

Through bioinformatics analysis, compared with normal tissues, genes such as TP53, CHEK2, TSC1, TSC2, NF1, NF2, SSTRs, GRPR, and NMBR were abnormally expressed in brain cancer.

Figure 1. Development and progression of astrocytic brain tumours.( Maciej S. Lesniak,et al.; 2004)

Brain tumors are associated with several familial cancer predisposition syndromes, study finds. These include Li-Fraumeni syndrome, neurofibromatosis, tuberous sclerosis, and Turcot syndrome. In these syndromes, individuals inherit a germline mutation in a tumor suppressor gene. Tumors kick in when the remaining copies of the tumor suppressor are mutated or silenced, resulting in cells with a growth advantage. Li-Fraumeni syndrome is caused by mutations in the cellular checkpoint genes TP53 and CHEK2. Turcot syndrome is caused by mutations in genes involved in DNA repair. Neurofibromatosis is caused by mutations in NF1 or NF2, while tuberous sclerosis is caused by mutations in TSC1 or TSC2. NF1, NF2, TSC1 and TSC2 are all involved in the downregulation of growth-promoting signaling pathways in cells. Thus, in neurofibromatosis and tuberous sclerosis, the risk of brain tumors may be increased because brain cells are primed to overgrow and then develop additional mutations that can form cancer. In addition, studies have found overexpressed GPCR receptors in brain and nervous system cancers. These receptors include somatostatin receptors (SSTR), bombesin receptors (BnR), such as GRP receptors, NMB receptors, and orphan receptors.

In addition to the above genes, there are interesting brain cancer-related genes that need to be explored and studied. Therefore, there is a need for an In Vivo transfection system that can precisely target brain cancer tissue and be taken up by tumor cells to function In Vivo. The system can help researchers overcome various challenges encountered during In Vivo transfection:

• Relevant molecular function studies can only be carried out in vitro, lacking important In Vivo data
• Using in vitro transfection system for In Vivo transfection, the transfection efficiency is very low;
• The In Vivo transfection system used is not specific to Brain cancer tissues and cells, and is toxic to the body;
• The In Vivo transfection system used cannot penetrate the Brain cancer tissue into the tumor tissue;
• The nucleic acid load of the In Vivo transfection system is low, and it is difficult to achieve the expected effect;
• Etc…

Our Advantage:

• We can provide an In Vivo transfection system for Brain cancer tissues and cells to achieve efficient transfection
• Our system can target multiple targets at the same time, improving targeting accuracy
• The In Vivo transfection system has low toxicity to the body and is safe to use
• In Vivo transfection system vectors can protect nucleic acids from degradation during In Vivo delivery
• Persistent knockout effect in experimental animals after a single injection
• The system load is high, and the transfection needs of different doses can be completed
• Professional design and service team to provide you with reliable service and technical support
• Timely feedback of technical reports

CD BioSciences specializes in developing transfection systems and customizing transfection reagents for gene transfection using our core technologies. With our high-quality products and services, your transfection results can be greatly improved. If you can't find a perfect In Vivo transfection system, you can contact us. We can provide one-to-one personal customization service.

References

1. Shah V, Kochar P. Brain Cancer: Implication to Disease, Therapeutic Strategies and Tumor Targeted Drug Delivery Approaches. Recent Pat Anticancer Drug Discov. 2018;13(1):70-85.
2. Zhao M, et al.; Online database for brain cancer-implicated genes: exploring the subtype-specific mechanisms of brain cancer. BMC Genomics. 2021, 22(1):458.
3. Wang X, et al.; Combinatorial therapeutic strategies for enhanced delivery of therapeutics to brain cancer cells through nanocarriers: current trends and future perspectives. Drug Deliv. 2022, 29(1):1370-1383.
4. Reilly KM. Brain tumor susceptibility: the role of genetic factors and uses of mouse models to unravel risk. Brain Pathol. 2009, 19(1):121-31.
5. Maciej S. Lesniak & Henry Brem. Targeted therapy for brain tumours. Nature Reviews Drug Discovery. 2004, volume 3, pages499–508

* For research use only. Not for use in clinical diagnosis or treatment of humans or animals.